Evidence map›Paper›PMID 42558961›Full record

ArticleTherapeutic advances in medical oncology2026

Real-world analysis of perioperative strategies for driver gene-positive resectable non-small cell lung cancer.

Xingpeng Wang, Kaiyue Wang, Baiyang Huang, Jiarui Zhao, Min Li, Jingyu Zhu, Jing Xu, Chaoran Zhu, Zihan Liu, Xiaohan Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xingpeng WangSchool of Clinical Medicine, Shandong Second Medical University, Weifang, China.
Kaiyue WangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Baiyang HuangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jiarui ZhaoDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Min LiDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jingyu ZhuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jing XuShandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Chaoran ZhuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Zihan LiuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Xiaohan WangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Menglin BaiDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Xue MengDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID https://orcid.org/0000-0001-6311-2649
Jinming YuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, No. 440, Jiyan Road, Jinan, Shandong 250117, China.ORCID https://orcid.org/0000-0001-5933-9912
Chenggang WangDepartment of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China.
Guoxin CaiDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, No. 440, Jiyan Road, Jinan, Shandong 250117, China.ORCID https://orcid.org/0009-0000-1130-8447

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The optimal perioperative treatment strategy for driver gene-positive non-small cell lung cancer (NSCLC) remains unclear. Objectives: To compare the prognostic outcomes of different perioperative strategies for patients with resectable driver gene-positive NSCLC. Design: Multicenter retrospective observational cohort study. Methods: We retrospectively evaluated patients with resectable AJCC 8th clinical stage II-IIIB driver gene-positive NSCLC who underwent neoadjuvant therapy or upfront surgery with adjuvant targeted therapy (US + ATT) at two institutions between 2021 and 2023. Treatment was classified as neoadjuvant targeted therapy (NTT), neoadjuvant chemoimmunotherapy (NCIT), neoadjuvant chemotherapy (NCT), or US + ATT. The primary endpoints were event-free survival (EFS) and overall survival (OS). Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Results: In total, 290 patients were included; the median follow-up was 31.2 months. Compared with NCT, NCIT was associated with longer EFS ( Conclusion: NCIT was associated with improved EFS in resectable driver gene-positive NSCLC, although a corresponding OS improvement was not observed. NTT + chemotherapy may offer better prognosis than NCT alone in EGFR‑mutant NSCLC.

Indexed as

event-free survivalneoadjuvantnon-small cell lung canceroverall survivalperioperative

Identifiers

PMID42558961
PMCPMC13438349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.